Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -60,692 | -45,525 | -30,079 | -14,950 | -33,277 |
| Depreciation Amortization | 2,277 | 1,646 | 1,054 | 512 | 1,821 |
| Other Working Capital | -700 | -59 | -2,947 | -1,340 | 966 |
| Other Operating Activity | 11,557 | 8,548 | 5,338 | 2,420 | 5,915 |
| Operating Cash Flow | $-47,558 | $-35,390 | $-26,634 | $-13,358 | $-24,575 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,263 | -2,867 | -2,280 | -1,089 | -2,219 |
| Investing Cash Flow | $-3,263 | $-2,867 | $-2,280 | $-1,089 | $-2,219 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -51 | -2 | -2 | N/A | -49 |
| Common Stock Issued | 783 | 627 | 595 | 282 | 77,539 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -355 |
| Financing Cash Flow | $732 | $625 | $593 | $282 | $77,135 |
| Beginning Cash Position | 193,434 | 193,434 | 193,434 | 193,434 | 143,093 |
| End Cash Position | 143,345 | 155,802 | 165,113 | 179,269 | 193,434 |
| Net Cash Flow | $-50,089 | $-37,632 | $-28,321 | $-14,165 | $50,341 |
| Free Cash Flow | |||||
| Operating Cash Flow | -47,558 | -35,390 | -26,634 | -13,358 | -24,575 |
| Capital Expenditure | -3,263 | -2,867 | -2,280 | -1,089 | -2,219 |
| Free Cash Flow | -50,821 | -38,257 | -28,914 | -14,447 | -26,794 |